[go: up one dir, main page]

WO2014013090A3 - Formulation comprenant du fingolimod amorphe - Google Patents

Formulation comprenant du fingolimod amorphe Download PDF

Info

Publication number
WO2014013090A3
WO2014013090A3 PCT/EP2013/073902 EP2013073902W WO2014013090A3 WO 2014013090 A3 WO2014013090 A3 WO 2014013090A3 EP 2013073902 W EP2013073902 W EP 2013073902W WO 2014013090 A3 WO2014013090 A3 WO 2014013090A3
Authority
WO
WIPO (PCT)
Prior art keywords
fingolimod
formulation
amorphous
pharmaceutical formulation
composite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2013/073902
Other languages
English (en)
Other versions
WO2014013090A2 (fr
Inventor
Deepak Murpani
Reinerus Gerardus Gieling
Lisardo ÁLVAREZ FERNÁNDEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Publication of WO2014013090A2 publication Critical patent/WO2014013090A2/fr
Publication of WO2014013090A3 publication Critical patent/WO2014013090A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un composite solide contenant une base de fingolimod et un copolymère d'acide méthacrylique et de divinylbenzène, une formulation pharmaceutique comprenant ledit composite, et l'utilisation du composite solide ou de la formulation pharmaceutique en tant que médicament, en particulier pour le traitement de la sclérose en plaques.
PCT/EP2013/073902 2013-05-06 2013-11-15 Formulation comprenant du fingolimod amorphe Ceased WO2014013090A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2013/059370 2013-05-06
EP2013059370 2013-05-06

Publications (2)

Publication Number Publication Date
WO2014013090A2 WO2014013090A2 (fr) 2014-01-23
WO2014013090A3 true WO2014013090A3 (fr) 2014-04-03

Family

ID=49622811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/073902 Ceased WO2014013090A2 (fr) 2013-05-06 2013-11-15 Formulation comprenant du fingolimod amorphe

Country Status (1)

Country Link
WO (1) WO2014013090A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015131034A (ru) * 2013-01-15 2017-02-01 Сан Фармасьютикал Индастрис Лтд. Устойчивая композиция, содержащая финголимод
WO2016042493A1 (fr) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Compositions pharmaceutiques de fingolimod

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008037421A2 (fr) * 2006-09-26 2008-04-03 Novartis Ag Composés organiques
EP2198857A1 (fr) * 2008-12-19 2010-06-23 Ratiopharm GmbH Comprimé dispersible oral
EP2505589A1 (fr) * 2011-04-01 2012-10-03 Johann Wolfgang Goethe-Universität Frankfurt am Main Nouveaux composés hétérocycliques de sphingolipides en tant que modulateurs de la signalisation de sphingolipides et leurs utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008037421A2 (fr) * 2006-09-26 2008-04-03 Novartis Ag Composés organiques
EP2198857A1 (fr) * 2008-12-19 2010-06-23 Ratiopharm GmbH Comprimé dispersible oral
EP2505589A1 (fr) * 2011-04-01 2012-10-03 Johann Wolfgang Goethe-Universität Frankfurt am Main Nouveaux composés hétérocycliques de sphingolipides en tant que modulateurs de la signalisation de sphingolipides et leurs utilisations

Also Published As

Publication number Publication date
WO2014013090A2 (fr) 2014-01-23

Similar Documents

Publication Publication Date Title
CA2956871C (fr) Composes actifs envers des bromodomaines
HK1211475A1 (en) Combination therapy
WO2014205389A8 (fr) Modulateurs de transport nucléaire et leurs utilisations
CA2894892A1 (fr) Derives d'acide boronique et leurs utilisations therapeutiques
WO2016011222A3 (fr) Polynucléotides circulaires
WO2013170068A3 (fr) Modulateurs du transport nucléaire et leurs utilisations
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
WO2015077503A8 (fr) Composés inhibiteurs de l'autotaxine
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
WO2014096425A3 (fr) Promédicaments de fumarate de monométhyle (mmf)
HK1218621A1 (zh) 用於治疗慢性炎症和炎性疾病的组合物及方法
HK1213779A1 (zh) 用於立即和延长释放的组合物
WO2015056094A3 (fr) Composition pharmaceutique comprenant un antagoniste de trpa1 et un agent analgésique
WO2011141488A3 (fr) Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone
WO2014106825A3 (fr) Procédés et dispositifs d'identification de notification médicale erronée
PH12012502083A1 (en) Manufacturing of active-free granules and tablets comprising the same
PH12012502082A1 (en) Combination of active loaded granules with additional actives
WO2016001937A3 (fr) Formulations pharmaceutiques à libération modifiée
CA2863376A1 (fr) Comprimes gastro-resistants
WO2012162439A3 (fr) Compositions comprenant de l'acide fusidique et leurs emballages
WO2014121137A3 (fr) Compositions et méthodes utilisables en vue du traitement de maladies neurodégénératives et autres
WO2014155389A3 (fr) Procédé de préparation de ticagrelor
WO2015082590A3 (fr) Dérivés de bis-mmf
WO2014125504A3 (fr) Compositions pharmaceutiques de fébuxostat

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13792896

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13792896

Country of ref document: EP

Kind code of ref document: A2